Zealand Pharma finds all patients for phase III study

A total of 108 patients have been enrolled in Zealand Pharma's crucial trial of glepaglutide as a treatment of short bowel syndrome.
Photo: Zealand Pharma / PR
Photo: Zealand Pharma / PR
by marketwire, translated by daniel pedersen

Biotech company Zealand Pharma has recruited all 108 patients required for a phase III study of its drug candidate glepaglutide, which is meant to treat short bowel syndrome, the company announces in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading